In conclusion, we outline here the importance of two drug mechanisms targeting HSC that may be relevant when treating NAFLD/NASH: PPARγ-stimulation and relaxation of contractile apparatus. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.